The currently available c-Abl inhibitors are imatinib, dasatinib, and nilotinib, all of which have been used for the treatment of CML, Ph+ALL, and gastrointestinal stromal tumor [36], [37], [38]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.